Back to List View Graph View

Bortezomib

Bortezomib (trade name Velcade) is a first-generation, reversible inhibitor of the 26S proteasome and one of the most pivotal agents in modern hematologic oncology.

Where the papers sit

12 papers from the last 6 months study bortezomib directly · updated from PubMed 9 Nov 2026

  • Myeloma Combination Therapy

    Daratumumab added to bortezomib, lenalidomide, and dexamethasone is pushing newly diagnosed myeloma therapy toward deeper responses and improved minimal residual disease outcomes. Safety analyses and interim-trial findings emphasize regimen tolerability and caution against premature efficacy conclusions. Treatment response is also being linked to circulating M-MDSC expansion, while MYBL2 loss may increase bortezomib sensitivity through CDKN3, PI3K/Akt, and ferroptosis pathways. Clinical benefit and mechanistic biomarkers still require integration.

    6 papers · 50%

  • Multiple Myeloma Treatment

    Proteasome-inhibitor combinations are being adapted for newly diagnosed multiple myeloma, particularly with renal impairment or high-risk disease. Pomalidomide–bortezomib–dexamethasone and selinexor-containing regimens seek deeper responses than older bortezomib–dexamethasone or thalidomide-based therapy. Renal rescue depends on rapid, substantial hematologic response, while progression-free survival remains a key endpoint. The optimal balance of efficacy, toxicity, and treatment intensity remains open.

    4 papers · 33.3%

  • Proteasome Inhibitor Sensitization

    Combination strategies are being used to overcome resistance to proteasome inhibition in bladder cancer and multiple myeloma. Nelfinavir targets NRF1-mediated proteasome bounce-back in gemcitabine/cisplatin-resistant bladder cancer, whereas triptonide blocks TRIP13-dependent DNA repair and enhances bortezomib activity. Both approaches aim to increase apoptosis by disabling compensatory survival or repair pathways. Evidence remains preclinical, leaving optimal combinations, selectivity, and clinical translation unresolved.

    2 papers · 16.7%

bortezomib chemical structure

Papers

The 12 papers from the last 6 months that study bortezomib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Myeloma Combination Therapy (6)
  1. Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study. Trials · 28 Aug 2026 PMID 42661196
  2. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
  3. Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clinical and translational science · 30 Jun 2026 PMID 42374568
  4. MYBL2 Knockdown Enhances Ferroptosis and Bortezomib Sensitivity by Transcriptionally Regulating CDKN3 and Inactivating PI3K/Akt Signaling in Multiple Myeloma. Journal of biochemical and molecular toxicology · 25 Jun 2026 PMID 42345518
  5. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
  6. The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749
Multiple Myeloma Treatment (4)
  1. Renal rescue in myeloma: How deep does the hematologic response need to be? Med (New York, N.Y.) · 9 Oct 2026 PMID 42854676
  2. Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003). Med (New York, N.Y.) · 9 Sept 2026 PMID 42716009
  3. Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease. Journal of nephrology · 24 Aug 2026 PMID 42634194
  4. Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of medicine · 3 Aug 2026 PMID 42544613
Proteasome Inhibitor Sensitization (2)
  1. Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine/cisplatin-resistant bladder cancer cells. Biochemical and biophysical research communications · 25 Sept 2026 PMID 42790027
  2. Triptonide enhances DNA damage by inhibiting TRIP13‑mediated DNA repair and synergizes with bortezomib to suppress multiple myeloma. International journal of oncology · 17 Jul 2026 PMID 42464653

By study type

Clinical trials (3)
  1. Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003). Med (New York, N.Y.) · 9 Sept 2026 PMID 42716009
  2. Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study. Trials · 28 Aug 2026 PMID 42661196
  3. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
Observational studies and case reports (4)
  1. Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease. Journal of nephrology · 24 Aug 2026 PMID 42634194
  2. Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of medicine · 3 Aug 2026 PMID 42544613
  3. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
  4. Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clinical and translational science · 30 Jun 2026 PMID 42374568
Human data, design not indexed (1)
  1. Renal rescue in myeloma: How deep does the hematologic response need to be? Med (New York, N.Y.) · 9 Oct 2026 PMID 42854676
Preclinical: animal, cell and lab studies (3)
  1. Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine/cisplatin-resistant bladder cancer cells. Biochemical and biophysical research communications · 25 Sept 2026 PMID 42790027
  2. Triptonide enhances DNA damage by inhibiting TRIP13‑mediated DNA repair and synergizes with bortezomib to suppress multiple myeloma. International journal of oncology · 17 Jul 2026 PMID 42464653
  3. MYBL2 Knockdown Enhances Ferroptosis and Bortezomib Sensitivity by Transcriptionally Regulating CDKN3 and Inactivating PI3K/Akt Signaling in Multiple Myeloma. Journal of biochemical and molecular toxicology · 25 Jun 2026 PMID 42345518
Unclassified: not yet indexed with MeSH (1)
  1. The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749